None
Quote | G1 Therapeutics Inc. (NASDAQ:GTHX)
Last: | $3.01 |
---|---|
Change Percent: | 0.67% |
Open: | $2.95 |
Close: | $3.01 |
High: | $3.07 |
Low: | $2.87 |
Volume: | 822,043 |
Last Trade Date Time: | 06/07/2024 03:00:00 am |
News | G1 Therapeutics Inc. (NASDAQ:GTHX)
2024-05-28 14:34:16 ET More on G1 Therapeutics G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Call Transcript Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript G1 Therapeu...
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to Historical Data for the ADC Alone - - Exploratory Analysis of a More Comparable Patient P...
Message Board Posts | G1 Therapeutics Inc. (NASDAQ:GTHX)
Subject | By | Source | When |
---|---|---|---|
Thinking through this more- arent most CRC tumors | sks144 | investorshub | 02/28/2023 1:44:07 AM |
Agreed! Lets see how much cash they have | stocksrising | investorshub | 02/16/2023 1:42:45 AM |
I hope they survive. Drug has real potential | sks144 | investorshub | 02/15/2023 5:59:20 PM |
Lets see how much cash they have after | stocksrising | investorshub | 02/13/2023 7:36:32 PM |
What? Oh my!!! lolzzzzzzz | SurgeGuy2.0 | investorshub | 11/01/2021 9:44:43 PM |
News, Short Squeeze, Breakout and More Instantly...
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 AD...
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to Historical Data for the ADC Alone - - Exploratory Analysis of a More Comparable Patient P...
RESEARCH TRIANGLE PARK, N.C., May 23, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today a...